Literature DB >> 8097241

Central mu opioid receptor-mediated changes in renal function in conscious rats.

D R Kapusta1, J C Obih, G F Dibona.   

Abstract

Studies were performed in conscious Sprague-Dawley rats to determine whether the renal sympathetic nerves contribute to the renal excretory responses produced by central mu opioid agonist administration. Intracerebroventricular, but not i.v. injection of the selective mu opioid agonist dermorphin (0.1 nmol/kg), produced an increase in urine flow rate and a sustained decrease in urine sodium excretion. These renal excretory responses were completely prevented by pretreatment with the selective mu opioid antagonist, beta-funaltrexamine (20 micrograms, i.c.v.). Central dermorphin administration did not alter glomerular filtration rate or effective renal plasma flow. In contrast, efferent renal sympathetic nerve activity increased over the same time frame as the reduction in urinary sodium excretion. To investigate whether the dermorphin-induced antinatriuretic response was mediated via the increase in renal sympathetic nerve activity, experiments were repeated in Sprague-Dawley rats that had undergone chronic bilateral renal denervation. In renal denervated rats, i.c.v. dermorphin produced similar diuretic and antinatriuretic responses as were seen in rats with an intact renal innervation. Together, these studies indicate that the changes in urine flow rate and urinary sodium excretion produced by i.c.v. dermorphin were not mediated via central induced changes in renal hemodynamics or sympathetic outflow to the kidneys. Because an antinatriuretic response occurred in renal denervated animals, this suggests that central mu opioid receptor agonists may exert an influence on tubular reabsorption of sodium via mu opioid receptor-mediated mechanisms independent of intact renal innervation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8097241

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  3 in total

Review 1.  Drug interactions with patient-controlled analgesia.

Authors:  Jorn Lotsch; Carsten Skarke; Irmgard Tegeder; Gerd Geisslinger
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Cardiovascular and renal effects of novel nonpeptide nociceptin opioid peptide receptor agonists.

Authors:  Ian B Denys; Juan Gao; Jane C Sutphen; Nurulain T Zaveri; Daniel R Kapusta
Journal:  Br J Pharmacol       Date:  2021-12-12       Impact factor: 8.739

Review 3.  Endogenous opiates: 1993.

Authors:  G A Olson; R D Olson; A J Kastin
Journal:  Peptides       Date:  1994       Impact factor: 3.750

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.